Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pieris Names New Chief Scientific Officer
Dr Audoly has held research and managerial positions of increasing responsibility, first as senior research scientist, department of inflammation, at Pfizer and then as senior research fellow, department
Dr Audoly has held research and managerial positions of increasing responsibility, first as senior research scientist, department of inflammation, at Pfizer and then as senior research fellow, department
The facility, the second FlexFactory at the company’s headquarters site, will expand Xcellerex’s capacity to provide bridge biomanufacturing services for clients that are planning or building their own
Almac IXRS 2.0 smart menu technology presents users with valid options and guides them to correct choices, directing their workflow in a logical and intuitive manner. According to
The solution for clinical trials combines Entra Health’s MyGlucoHealth Wireless blood glucose meter with PHT’s ePRO System to create an automated glucose monitoring and ePRO solution. The integration
Algicell Ag is an antimicrobial silver alginate dressing that delivers 1.4% ionic silver at a slow consistent release rate for broad-spectrum efficacy. Derma Sciences claimed that Algicell Ag
Tesetaxel is a late Phase 2 oncology oral taxane product. The data were presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in
Aeterna Zentaris said that AEZS-108 is in a Phase 2 trial conducted in Europe by the German AGO Study Group (Study AGO-GYN5), in advanced ovarian and endometrial cancer,
The license is extended to register, manufacture and commercialise Tapentadol in additional regions, including selected Asia Pacific, Latin American, African, and New European countries including Turkey and Greece,
The collaboration is to develop and market Durect’s Posidur (Saber-bupivacaine) a long-acting version of the anesthetic bupivacaine currently in Phase III clinical trials. Reportedly, Hospira is expected to
As per the terms of the agreement, Sanofi Pasteur and its affiliates acquire exclusive access to Vivalis’ platform for the discovery of fully human monoclonal antibodies targeting infectious